Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,302
  • Shares Outstanding, K 78,259
  • Annual Sales, $ 101,210 K
  • Annual Income, $ -570 K
  • EBIT $ 7 M
  • EBITDA $ 1 M
  • 60-Month Beta 1.07
  • Price/Sales 0.85
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 163.96% ( +46.29%)
  • Historical Volatility 82.55%
  • IV Percentile 53%
  • IV Rank 20.53%
  • IV High 739.39% on 04/22/24
  • IV Low 15.34% on 09/19/24
  • Put/Call Vol Ratio 1.01
  • Today's Volume 494
  • Volume Avg (30-Day) 253
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 6,199
  • Open Int (30-Day) 3,980

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.20
  • Number of Estimates 5
  • High Estimate -0.01
  • Low Estimate -0.53
  • Prior Year 0.01
  • Growth Rate Est. (year over year) -2,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8350 +30.54%
on 11/21/24
1.4200 -23.24%
on 12/04/24
+0.2199 (+25.27%)
since 11/20/24
3-Month
0.8330 +30.85%
on 11/19/24
1.4200 -23.24%
on 12/04/24
-0.1000 (-8.40%)
since 09/20/24
52-Week
0.8330 +30.85%
on 11/19/24
5.8500 -81.37%
on 05/01/24
-0.2500 (-18.66%)
since 12/20/23

Most Recent Stories

More News
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy

Ultragenyx Pharmaceutical RARE announced that it has submitted a biologics license application (BLA) to the FDA for its UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome...

CTMX : 1.0900 (-0.91%)
RARE : 44.22 (+1.73%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Krystal Biotech KRYS announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung.The...

KRYS : 164.83 (+2.49%)
CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

Shares of Edgewise Therapeutics EWTX were up more than 18% on Monday after it announced positive results from the mid-stage CANYON study on its lead pipeline drug, sevasemten, in patients with a rare genetic...

CTMX : 1.0900 (-0.91%)
EWTX : 30.78 (-0.06%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Shares of Editas Medicine EDIT plunged 23.8% on Dec. 13 after it announced a strategic decision to end the development of its lead gene editing therapy, reni-cel, following the failure of an extensive...

CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
EDIT : 1.3100 (-2.24%)
SPRO : 0.9551 (-4.30%)
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408

Krystal Biotech, Inc. KRYS announced initial clinical data updates on its two inhaled genetic medicine pipeline candidates, KB407 and KB408, which are being developed in early-stage studies for treating...

KRYS : 164.83 (+2.49%)
CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Shares of Q32 Bio QTTB lost nearly 77% yesterday after it reported mixed results from two separate phase IIa studies evaluating its investigational drug bempikibart  one in atopic dermatitis (AD or eczema)...

CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
QTTB : 3.59 (+7.49%)
SPRO : 0.9551 (-4.30%)
Grifols Stock Declines After Brookfield Drops Buyout Offer

Shares of Grifols GRFS lost over 7% on Wednesday after the company announced that Canada-based Brookfield Asset Management has withdrawn its plan to acquire it.Both parties likely failed to arrive at a...

CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
GRFS : 7.51 (-2.72%)
SPRO : 0.9551 (-4.30%)
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

CTMX : 1.0900 (-0.91%)
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Jazz Pharmaceuticals JAZZ announced that the FDA has granted accelerated approval to its intravenously administered drug zanidatamab for certain patients with biliary tract cancer (BTC). The drug will...

CTMX : 1.0900 (-0.91%)
JAZZ : 122.97 (+0.10%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Shares of Grifols GRFS lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for €6.45 billion...

CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
GRFS : 7.51 (-2.72%)
SPRO : 0.9551 (-4.30%)

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 1.1867
2nd Resistance Point 1.1433
1st Resistance Point 1.1167
Last Price 1.0900
1st Support Level 1.0467
2nd Support Level 1.0033
3rd Support Level 0.9767

See More

52-Week High 5.8500
Fibonacci 61.8% 3.9335
Fibonacci 50% 3.3415
Fibonacci 38.2% 2.7495
Last Price 1.0900
52-Week Low 0.8330

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar